Clinical utility of degradomics as predictors of complications and clinical outcome in aneurysmal subarachnoid hemorrhage

• Main Authors: Shadi Bsat, Hani Chanbour, Ayman Bsat, Safwan Alomari, Charbel Moussalem, Mohamad Nabih El Houshiemy, Ibrahim Omeis
• Format: Article
• Language: English
• Published: IMR (Innovative Medical Research) Press Limited 2021-06-01
• Series: Journal of Integrative Neuroscience
• Subjects: degradomics; degradomes; proteases; aneurysm; subarachnoid hemorrhage; substrates; blood-brain barrier
• Online Access: https://jin.imrpress.com/fileup/1757-448X/PDF/1625014745856-1750375122.pdf

Most of the debilitating conditions following aneurysmal subarachnoid hemorrhage result from symptomatic cerebral vasospasm and delayed cerebral ischemia. Several scales are being used, but they still lack objectivity and fail to quantify complications considered essential for prognostication routine use of biomarkers to predict complications and outcomes after aneurysmal rupture is still experimental. Degradomics were studied extensively in traumatic brain injury, but there is no discussion of these biomarkers related to aneurysmal subarachnoid hemorrhage. Degradomics involve the activation of proteases that target specific substrates and generate specific protein fragments called degradomes. While the proteolytic activities constitute the pillar of development, growth, and regeneration of tissues, dysregulated proteolysis resulting from pathological conditions like aneurysmal subarachnoid hemorrhage ends up in apoptotic processes and necrosis. To our knowledge, this is the first overview that lists a panel of degradomics with cut-off values in serum and cerebrospinal fluid, where specificity and sensitivity are only found in Kallikrein 6, Ubiquitin C Terminal Hydrolase 1 and Alpha-II-Spectrin.